GenMark Diagnostics (GNMK) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GenMark Diagnostics Reports First Quarter 2018 Results
May 1, 2018 4:05 PM EDTCARLSBAD, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2018.
Highlights
Revenues of $20.6 million, an increase of 65% over the prior year periodePlex net new placements of 32 analyzers, expanding the global installed base to 228 placementsFive abstracts and posters on the benefits of ePlex BCID panels presented at ECCMID, the largest microbiology meeting in EuropeWere off to a solid start in 2018, with revenue... More
